Dr. Reddy’s closes acquisition over the Novartis’ Habitrol brand


Dr. Reddy’s Laboratory today announced acquisition has closed over the Novartis’ Habitrol brand for the Consumer Health.
A company said on a press release, Habitrol brand is an over-the-counter nicotine substitute therapy transdermal patch. United States Federal Trade Commission was issued the permission order for completing the acquisition on November 26.
Previously, DRL had entered into an asset purchase agreement with Novartis’ Habitrol brand to acquire the titles, rights as well as market the product in U.S. market.
Earlier today, DRL has assumed accountability for the product.
With this closure, DRL has unspecified accountability for the product. Shipments of the product in the market will begin shortly, said the release.